Flexion Therapeutics Inc. (NASDAQ:FLXN) was up 6.1% on Wednesday . The stock traded as high as $17.03 and last traded at $16.50, with a volume of 356,227 shares trading hands. The stock had previously closed at $15.55.

Several equities research analysts have recently weighed in on FLXN shares. Cantor Fitzgerald reissued a “buy” rating and issued a $44.00 price target on shares of Flexion Therapeutics in a research note on Friday, March 11th. Needham & Company LLC reaffirmed a “buy” rating and set a $28.00 target price on shares of Flexion Therapeutics in a research note on Monday, April 4th. Wells Fargo & Co. initiated coverage on Flexion Therapeutics in a research note on Tuesday, May 3rd. They set an “outperform” rating for the company. Zacks Investment Research cut Flexion Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, May 17th. Finally, Janney Montgomery Scott reaffirmed a “buy” rating and set a $30.00 target price on shares of Flexion Therapeutics in a research note on Friday, May 27th. One analyst has rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $31.81.

The stock’s market cap is $338.22 million. The stock has a 50-day moving average of $14.38 and a 200 day moving average of $12.86.

Flexion Therapeutics (NASDAQ:FLXN) last released its earnings results on Thursday, May 12th. The specialty pharmaceutical company reported ($0.78) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.61) by $0.17. Equities research analysts expect that Flexion Therapeutics Inc. will post ($2.84) EPS for the current year.

In related news, Director Samuel D. Colella bought 714,285 shares of the stock in a transaction dated Wednesday, June 8th. The stock was bought at an average price of $14.00 per share, with a total value of $9,999,990.00. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Samuel D. Colella bought 6,778 shares of the stock in a transaction dated Monday, June 20th. The stock was bought at an average cost of $13.84 per share, with a total value of $93,807.52. Following the purchase, the director now owns 3,435 shares in the company, valued at approximately $47,540.40. The disclosure for this purchase can be found here.

Other hedge funds and institutional investors have made changes to their positions in the company. Jennison Associates LLC increased its position in shares of Flexion Therapeutics by 2.7% in the fourth quarter. Jennison Associates LLC now owns 2,907,755 shares of the specialty pharmaceutical company’s stock worth $56,032,000 after buying an additional 76,487 shares in the last quarter. Schroder Investment Management Group increased its position in shares of Flexion Therapeutics by 21.0% in the fourth quarter. Schroder Investment Management Group now owns 470,200 shares of the specialty pharmaceutical company’s stock worth $9,061,000 after buying an additional 81,500 shares in the last quarter. Wells Fargo & Company MN increased its position in shares of Flexion Therapeutics by 16.2% in the fourth quarter. Wells Fargo & Company MN now owns 430,545 shares of the specialty pharmaceutical company’s stock worth $8,296,000 after buying an additional 59,866 shares in the last quarter. Oxford Asset Management acquired a new position in shares of Flexion Therapeutics during the fourth quarter worth about $1,901,000. Finally, Jennison Associates increased its position in shares of Flexion Therapeutics by 35.1% in the third quarter. Jennison Associates now owns 2,831,268 shares of the specialty pharmaceutical company’s stock worth $42,073,000 after buying an additional 736,261 shares in the last quarter.

Flexion Therapeutics, Inc is a specialty pharmaceutical company. The Company is focused on the development and commercialization of therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis and post-operative pain. The Company’s portfolio of product candidates addresses the OA pain treatment spectrum, from moderate to severe pain.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.